Lexaria Bioscience (LEXX) Earnings Analysis

Lexaria Bioscience (LEXX) next reports earnings on 2026-10-28, consensus EPS -0.06 USD. Last quarter (2026-07-13) it missed with EPS -0.08 USD vs -0.06 USD est (-33.3%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E -1.58.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does LEXX next report earnings?

Next earnings date2026-10-28
Consensus EPS estimate-0.06 USD
Revenue estimate0.00B

LEXX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-07-13-0.08 USD-0.06 USD-33.3%Miss
2026-04-13-0.06 USD-0.1 USD+40%Beat
2026-01-13-0.07 USD-0.13 USD+46.2%Beat
2025-11-26-0.13 USD-0.16 USD+18.8%Beat
2025-07-14-0.21 USD-0.15 USD-40%Miss
2025-04-14-0.15 USD-0.16 USD+6.3%Beat
2025-01-10-0.16 USD-0.12 USD-33.3%Miss
2024-11-26-0.15 USD-0.11 USD-36.4%Miss

Beat rate: 4/8 (50%) over reported quarters with consensus data.

LEXX valuation and analyst view

Trailing P/E-1.58
Trailing EPS-0.3117 USD
Price / book2.93
Dividend yield0.00%
Market cap0.01B
Analyst consensusBuy (2 buy / 0 hold / 0 sell)
Avg price target1.5 USD

Related research pages

Frequently asked questions

When is Lexaria Bioscience (LEXX)'s next earnings date?

Lexaria Bioscience is next scheduled to report on 2026-10-28, with a consensus EPS estimate of -0.06 USD and revenue estimate of 0.00B.

Did LEXX beat earnings last quarter?

In its 2026-07-13 report, LEXX posted EPS of -0.08 USD versus a -0.06 USD estimate — a miss of 33.3%.

What is LEXX's earnings track record?

Over the last 8 reported quarters with consensus data, LEXX beat estimates 4 times (50%).

What is LEXX's current P/E ratio and EPS?

LEXX trades at a trailing P/E of -1.58 on trailing EPS of -0.31170078566716564 USD.

What do analysts rate LEXX?

Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 1.5 USD.